Thalidomide and lenalidomide: Mechanism-based potential drug combinations
2008; Taylor & Francis; Volume: 49; Issue: 7 Linguagem: Inglês
10.1080/10428190802005191
ISSN1042-8194
AutoresSonia Vallet, Antonio Palumbo, Noopur Raje, Mario Boccadoro, Kenneth C. Anderson,
Tópico(s)Histone Deacetylase Inhibitors Research
ResumoThalidomide and its analogue lenalidomide are potent anti-inflammatory, anti-angiogenic and immunomodulatory drugs, successfully used for the treatment of hematological cancers, in particular multiple myeloma (MM). Both drugs reveal a dual mechanism of action: they target tumour cells by direct cytotoxicity and, indirectly, by interfering with several components of the bone marrow microenvironment. Lenalidomide and thalidomide are versatile drugs with a broad range of activities that potentiate the anti-MM effects of conventional and novel agents. Here, we review the mechanism of action of these drugs, providing a rationale for combination studies in order to improve patient outcome and reduce side effects.
Referência(s)